Trial ALS drug shows potential to drag out patient endurance Kumar Jeetendra | October 18, 2020 An experimental medicine that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the capacity to also prolong patient survival. The findings come from a clinical trial conducted by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts …
Eli Lilly delays preliminary of antibody drug Donald Trump promoted as COVID-19 ‘cure’ over wellbeing concern Kumar Jeetendra | October 14, 2020 Eli Lilly and Co said on Tuesday the clinical trial of its COVID-19 antibody treatment similar to one taken by US President Donald Trump has been paused due to a safety concern. Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc that he received for his COVID-19, as compared to …
Johnson and Johnson stops preliminaries because of unexplained ailment in member Kumar Jeetendra | October 13, 2020 Johnson & Johnson said on October 12 it has temporarily paused clinical trials of its own COVID-19 vaccine candidate because of an unexplained illness in a research participant. In a statement, the company said that the participant’s illness has been reviewed and assessed by an independent data and safety monitoring board, and its clinical and …
Pfizer changes convention for virus vaccine: study Kumar Jeetendra | October 13, 2020 Drugmaker Pfizer has modified the protocol for its late-stage study of its vaccine against the new coronavirus, this time to include more young participants. The company said on Monday that it’s received permission from the Food and Drug Administration to include adolescents aged 12 through 15 in its global COVID-19 vaccine study. New York-based Pfizer …
Bharat Biotech requested to submit total phase 2 information of its COVID-19 antibody before ph 3 preliminary Kumar Jeetendra | October 10, 2020 According to officials, the Hyderabad-based vaccine manufacturer applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to run phase-3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate. The firm in its program said that the study would cover 28,500 subjects aged 18 years and above and would …
AstraZeneca could benefit from COVID-19 antibody as right on time as July Kumar Jeetendra | October 8, 2020 AstraZeneca could start profiting from the COVID-19 vaccine as soon as July next year, the Financial Times reported Wednesday, citing a memo showing the British drugmaker can declare when it considers the pandemic to have ended. The London-listed firm previously said it wouldn’t profit from the vaccine”during the pandemic”, and the report attributes the development …
CellGenix Completes Facility Expansion to Stay Ahead of the Increasing Demand for GMP Raw Materials Kumar Jeetendra | October 8, 2020 FREIBURG, Germany, October 08, 2020 / B3C newswire / — CellGenix GmbH, a pioneer for GMP grade reagents and a leading global supplier of high quality raw and ancillary materials for cell and gene therapies, announces the completion of the second phase of their facility expansion. CellGenix has reconstructed and expanded their production facility for …
Hamdard Laboratories Launches ‘Immunity Booster’ and ‘Respiratory Health’ Kits Kumar Jeetendra | October 8, 2020 New Delhi, October 8, 2020: To offer complete wellness and health solutions, Hamdard Laboratories (Medicine Division), India’s most trusted Unani brand, today introduced ‘Immunity Booster’ and ‘Respiratory Health’ Kits to build a strong immunity and upkeep respiratory health system. The Unani medicine Kits have some amazing health and wellness products which are known for their …
Biocartis Announces Market Release of SeptiCyte® RAPID test on Idylla™ Kumar Jeetendra | October 7, 2020 Mechelen, Belgium, 6 October 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the market release of SeptiCyte® RAPID on Idylla™ as a CE-marked IVD test. SeptiCyte® RAPID is a host-response test1 that distinguishes sepsis from non-infectious systemic inflammation in patients suspected of sepsis and …
Glenmark Pharma gets USFDA gesture to showcase drug for backsliding numerous sclerosis Kumar Jeetendra | October 7, 2020 Drug major Glenmark Pharma on Wednesday said it has received final approval from the US health regulator for Dimethyl Fumarate delayed-release capsules, used for treatment of relapsing forms of multiple sclerosis in adults. Quoting IQVIA sales data for the 12 month period ending August 2020, Glenmark said Tecfidera delayed-release capsules, 120 mg and 240 mg, …
Lupin gets USFDA gesture to showcase drug for treating backsliding various sclerosis Kumar Jeetendra | October 6, 2020 The company has received approval from the United States Food and Drug Administration (USFDA) to advertise its own Dimethyl Fumarate delayed-release capsules in the strengths of 120 mg and 240 mg, Lupin said in a statement. The item is a generic version of Biogen Inc”s Tecfidera delayed-release capsules at the same strengths, it added. The …
Moderna antibody preliminary temporary workers neglect to select enough minorities, inciting lull Kumar Jeetendra | October 6, 2020 Private contractors hired by Moderna Inc to recruit volunteers for its coronavirus vaccine trial failed to enrol enough Black, Latino and Native American participants to ascertain how well the vaccine works in such populations, company executives and vaccine researchers told Reuters. To compensate for the shortfall, Moderna slowed registration of its late-stage trial and educated …
